ASH Clinical News May 2015 | Page 35

Median Progression-Free Survival (PFS)
Rd Continuous (n=535) 25.5 mo (95% CI 20.7, 29.4)
Rd18
(n=541) 20.7 mo (95% CI 19.4, 22.0)
MPT
(n=547) 21.2 mo (95% CI 19.3, 23.2)

100

Survival Probability (%)

80
Rd Continuous vs MPT
Rd Continuous vs Rd18
Rd18 vs MPT

60

Logrank P value (2-sided)
HR (95% CI)
0.72 (0.61, 0.85) P<0.0001
0.70 (0.60, 0.82)
1.03 (0.89, 1.20)

Planned duration of
treatment in the Rd18
40 and MPT arms was
18 months
20

0

0

1

2

3

4

5

Progression-Free Survival (Years)
• PFS
Rd Continuous
535
Rd18
541
MPT
547
Study design: The MM-020

Events: Rd Continuous=278/535 (52.0%), Rd18=348/541105
(64.3%), MPT=334/547 (61.1%)2
400
319
265
218
168
55
19
391
380
(FIRST)

319
265
167
304
170
compared244
REVLIMID +

108
116
low-dose

56
30
58
28
dexamethasone (Rd)

7
2
6
1
Continuous until

0
0
0
progression,

trial
fixed-cycle
MPT, and fixed-cycle Rd18. MM-020 was a Phase 3, randomized, multicenter, open-label, 3-arm study enrolling 1623 newly diagnosed
Number of was gi ٕ